ELEKTA AB/ADR (OTCMKTS:EKTAY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday, Zacks.com reports. The firm currently has a $14.00 price target on the stock. Zacks Investment Research‘s target price points to a potential upside of 1.74% from the stock’s previous close.
According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “
Separately, Jefferies Financial Group raised shares of ELEKTA AB/ADR from an “underperform” rating to a “hold” rating in a report on Tuesday, July 16th.
About ELEKTA AB/ADR
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
Featured Article: Why are percentage gainers important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.